ライフサイエンスコーパス: vulvar

1 nogenital cancers (273 cervical, 24 anal, 67 vulvar, 12 vaginal, and 24 penile cancers) with prediagn

2 e United States, as well as 32 prostatic, 30 vulvar, 24 ovarian, 20 cervical, and 30 testicular cance

3 follows: cervical (50.5%), vaginal (48.4%), vulvar (42.4%), penile (41.5%), anal (41.5%), and oropha

4 was lower (58.3%) than cervical (73.6%) and vulvar (72.1%) detection (P = 0.05 and 0.07, respectivel

5 metastatic disease (cervical, 78.9%; vaginal/vulvar, 80.0%).

6 In vulvar and cervical carcinomas, sentinel node identifica

7 Vulvar and cervical HPV16 prevalence within the control

8 this intention-to-treat analysis, VE against vulvar and cervical HPV16/18 were comparable 4 years fol

9 ping on voided-urine and clinician-collected vulvar and cervical samples from 72 women undergoing col

10 sit of the Costa Rica Vaccine Trial provided vulvar and cervical samples.

11 Subrenal xenografts of ROPV-infected rabbit vulvar and penile sheath tissues were strongly positive

12 EMPD arises most commonly on the vulvar and penoscrotal skin.

13 vical cancer, and now also for prevention of vulvar and vaginal cancers, confirmed 98-100% vaccine ef

14 ation, the incidence of high-grade cervical, vulvar and vaginal disease related to HPV 31, 33, 45, 52

15 Symptoms and signs can include intense vulvar and vaginal itching, low back pain, uterine cramp

16 enotype detectable in 25% of urine, 33.8% of vulvar, and 31.9% of cervical samples overall, with prev

17 erine, cervical, endometrial, vaginal and/or vulvar, and other gynecological cancers were reviewed to

18 hampion HPV vaccination to prevent cervical, vulvar, and vaginal cancers, even though these benefits

19 cytologic and HPV testing) and any cervical, vulvar, and vaginal histopathological findings for all w

20 vaginal (aOR = 0.30; 95% CI: 0.14-0.66), and vulvar (aOR = 0.34; 95% CI: 0.15-0.75) cancers compared

21 vaginal (aOR = 0.40; 95% CI: 0.21-0.76), and vulvar (aOR = 0.51; 95% CI: 0.27-0.97) cancers.

22 We compared cervical and vulvar areas of the vagina in young nullipara and older

23 In women with symptoms of vaginal and/or vulvar atrophy, lubricants in addition to vaginal moistu

24 l, anal, oropharyngeal, penile, vaginal, and vulvar) awareness and sociodemographic and behavioral fa

25 We obtained a vulvar biopsy of autologous tissue from every patient.

26 .4%), and from 81.1% to 72.6% for those with vulvar cancer (AAPC, -1.3%; 95% CI, -1.6% to -0.9%).

27 ), and from 12.3% to 36.9% for patients with vulvar cancer (AAPC, 10.7%; 95% CI, 8.0% to 13.5%) cance

28 t trial, including patients with early-stage vulvar cancer (diameter < 4 cm) without signs of lymph n

29 gen International Study on Sentinel nodes in Vulvar cancer (GROINSS-V)-II investigated whether inguin

30 r, with the greatest disparity occurring for vulvar cancer (IRR, 1.44; 95% CI, 1.38-1.51).

31 h node (LN) status in patients with invasive vulvar cancer (VC) scheduled for inguinofemoral LN disse

32 f western Washington who were diagnosed with vulvar cancer between April 1991 and June 1994.

33 from two different groups: 265 subjects in a vulvar cancer case-control study and 107 healthy volunte

34 Like other rare cancers, vulvar cancer lags behind in the identification and opti

35 e to inguinofemoral lymphadenectomy (IFL) in vulvar cancer patients with a metastatic sentinel node (

36 e I to IV endometrial, ovarian, cervical, or vulvar cancer within this time frame.

37 (vulvar intraepithelial neoplasia grade 2/3, vulvar cancer), and vaginal disease (vaginal intraepithe

38 sia grade 3, 4.97 (95% CI, 3.26 to 7.57) for vulvar cancer, 13.66 (93% CI, 9.69 to 19.25) for vulvar

39 highest solid tumor O/E ratios were 4317 for vulvar cancer, 2362 for esophageal cancer, and 706 for h

40 uch as endometrial cancer, uterine sarcomas, vulvar cancer, and vaginal carcinoma but with less well

41 1 null genotype are not at increased risk of vulvar cancer.

42 e GSTM1 null genotype are at altered risk of vulvar cancer.

43 e I to IV endometrial, ovarian, cervical, or vulvar cancer.

44 ual dysfunction and has been associated with vulvar cancer.

45 ed in studies of cervical adenocarcinoma and vulvar cancer.

46 , or 3 CIN; cervical cancer; vaginal cancer; vulvar cancer; anal cancer; head and neck cancer; genita

47 recurrent/metastatic cervical and vaginal or vulvar cancers is promising and warrants additional inve

48 breast, 5; pancreas, 5; ovarian/endometrial/vulvar cancers, 3; and de novo cholangiocarcinoma, 4).

49 ack individuals, especially for cervical and vulvar cancers, potentially due to disproportionately hi

50 h recurrent/metastatic cervical, vaginal, or vulvar cancers.

51 e to patients with cervical, endometrial, or vulvar cancers.

52 and 20.0% (95% CI, 0.5 to 71.6) for vaginal/vulvar cancers.

53 port the concept of at least two pathways in vulvar carcinogenesis.

54 arcinoma (approximately 100%) and similar to vulvar carcinoma (approximately 50%).

55 Treatment of vulvar carcinoma (VC) is challenging.

56 g malignancies: 9 myelodysplasia/leukemia, 1 vulvar carcinoma and metastatic melanoma, 1 cervical car

57 symptom control, scarring, and occurrence of vulvar carcinoma between compliant and partially complia

58 amous epithelial alterations associated with vulvar carcinoma, including hyperplasia and lichen scler

59 complicated by loss of vulvar structure and vulvar carcinoma.

60 at increased risk of development of invasive vulvar carcinoma.

61 of loss of heterozygosity (LOH) within four vulvar carcinomas and in adjacent vulvar epithelia.

62 (aneuploidy) occurs in the skin surrounding vulvar carcinomas.

63 The vulvar cell lines were the most sensitive, and the ovari

64 much more potent growth inhibitor of the two vulvar cell lines, which is consistent with strong RARga

65 Women collected daily genital swabs of the vulvar, cervicovaginal, and perianal areas for HSV cultu

66 the single responding patient in the vaginal/vulvar cohort.

67 cohort and all five patients in the vaginal/vulvar cohort; there were no treatment-related deaths.

68 s (HPV) infections, and chronic inflammatory vulvar dermatoses.

69 skin biopsies failed to reveal an underlying vulvar dermatosis or autoimmune bullous disorder.

70 content of healthy (HE, n = 40) and purulent vulvar discharge sows (VD, n = 270) by a culture-depende

71 inal microbiota between healthy and purulent vulvar discharge sows, although not extreme, could be du

72 Purulent vulvar discharges, primarily caused by genito-urinary tr

73 be considered in patients with complaints of vulvar discomfort during the season of cedar pollen diss

74 inoma in situ, invasive cervical carcinoma), vulvar disease (vulvar intraepithelial neoplasia grade 2

75 Vulvar diseases are a neglected area of women's health,

76 fects a spectrum of women with granulomatous vulvar diseases, human papillomavirus (HPV) infections,

77 owed that chronic vulval pain (vulvodynia or vulvar dysaesthesia) is associated with worse depressive

78 d close surveillance for local recurrence in vulvar EMPD and metastatic recurrence in perianal EMPD.

79 Most vulvar EMPD cases were asymptomatic, and diagnosis was r

80 Although most vulvar EMPD cases were intraepidermal (1247/1773 [70.3%]

81 ctice may include less morbid treatments for vulvar EMPD, which is primarily epidermal, and close sur

82 in one CKI-responsive cell line (A431 human vulvar epidermoid carcinoma cells with functional Rb) an

83 ithin four vulvar carcinomas and in adjacent vulvar epithelia.

84 hat many genetic alterations in the adjacent vulvar epithelium are not directly related to the invasi

85 rrounding vulvar skin were obtained from all vulvar excisions performed for squamous neoplasia at Alb

86 the agreement of urine HPV with cervical and vulvar HPV was moderate (kappa = 0.55) and substantial (

87 Independent risk factors for vulvar HPV were similar to cervix and included: age (adj

88 VE against 1-time detection of vulvar HPV16/18 among HPV vaccinated versus unvaccinated

89 Vulvar HPV16/18 VE (54.1%; 95% confidence interval [CI],

90 Vaccine efficacy (VE) against vulvar human papillomavirus (HPV) infection has not been

91 ntraepithelial neoplasia and, in some cases, vulvar hyperplasia, and lichen sclerosis.

92 gated in paraffin-embedded VSCC and adjacent vulvar intraepithelial neoplasia (VIN) and VLS specimens

93 ites of normal squamous mucosa, hyperplasia, vulvar intraepithelial neoplasia (VIN), and carcinoma we

94 Samples of SCC, vulvar intraepithelial neoplasia (VIN), and surrounding

95 l assay supports a monoclonal derivation for vulvar intraepithelial neoplasia and, in some cases, vul

96 nvasive cervical carcinoma), vulvar disease (vulvar intraepithelial neoplasia grade 2/3, vulvar cance

97 ar cancer, 13.66 (93% CI, 9.69 to 19.25) for vulvar intraepithelial neoplasia grade 3, 86.08 (95% CI,

98 Biopsy-proved squamous cell carcinoma or vulvar intraepithelial neoplasia occurred during follow-

99 Provided cancer is not suspected, usual-type vulvar intraepithelial neoplasia treatment, including me

100 lasms of the female genital tract, including vulvar intraepithelial neoplasia, presumably are derived

101 ective and tolerable for treating usual-type vulvar intraepithelial neoplasia?

102 Of 8 vulvar intraepithelial neoplasias analyzed, 7 were score

103 Vulvar lesions failed to heal in association with trials

104 Adult vulvar lichen sclerosis (VLS) may be complicated by loss

105 Vulvar lichen sclerosus (VLS) is a progressive skin dise

106 f vulvar squamous cell carcinoma (VSCC) from vulvar lichen sclerosus (VLS) is unknown.

107 roids are the current first-line therapy for vulvar lichen sclerosus (VLS).

108 e this burden, the molecular pathogenesis of vulvar lichen sclerosus is not well-understood, limiting

109 reveals keratinocytes as central players in vulvar lichen sclerosus pathogenesis and identifies pote

110 anges across multiple cell types in lesional vulvar lichen sclerosus skin, including keratinocyte str

111 Physicians managing patients with vulvar LS should be aware of the possibility of vaginal

112 Two cases of severe vulvar LS with vaginal involvement are reported.

113 robiome and Actinomyces and Ezakiella in the vulvar microbiome were significantly associated with lic

114 Staphylococcus were the most abundant in the vulvar microbiome.

115 This study investigated the vaginal and vulvar microbiomes of 27 post-menopausal women with lich

116 However, inflammation of the vulvar mucosa due to sensitization to cedar pollen is no

117 nty-four patients (cervical, n = 19; vaginal/vulvar, n = 5) were enrolled.

118 alignancies, Kaposi's sarcomas, and cervical/vulvar neoplasms are the most common, but visceral malig

119 The rate of high-grade cervical, vulvar, or vaginal disease irrespective of HPV type (i.e

120 The rate of high-grade cervical, vulvar, or vaginal disease related to HPV-31, 33, 45, 52

121 of two cell lines each derived from cervix, vulvar, ovarian, and head/neck tumors with similar effic

122 and vulvodynia, a debilitating, unexplained vulvar pain condition.

123 dentified 125 women experiencing symptoms of vulvar pain consistent with vulvodynia and 125 age- and

124 tment for socioeconomic position, women with vulvar pain versus controls were 2.6 times more likely t

125 in group (atrial fibrillation, pancreatitis, vulvar pain, chest tube malfunction and conversion to op

126 subsequent malignancies (cervical, vaginal, vulvar, penile, anal, tongue, tonsillar, and oropharynge

127 everal other cancer types including vaginal, vulvar, penile, and oropharyngeal cancers.

128 Swabs of labial, vulvar, perineal, perianal, endocervical, and ectocervic

129 stension, cutaneous thermal stimulation, and vulvar pressure) to establish and validate generalizable

130 ine, salivary, small-cell lung, thyroid, and vulvar), progression on or intolerance to one or more li

131 from the Chauvet paintings reveal that the "vulvar" representations from southwestern France are as

132 The vulvar samples were mainly polymicrobial (n = 25).

133 nding sensitivity and specificity values for vulvar sampling were 92% (95% CI = 74 to 99) and 40.5% (

134 cal benefit to some patients with vaginal or vulvar SCC and is overall safe to utilize in this popula

135 nt a case series of patients with vaginal or vulvar SCC who were treated with single-agent pembrolizu

136 One case of recurrent vulvar SCC with multiple surgical resections and prior p

137 amous cell carcinoma [SCC], anal/rectal SCC, vulvar SCC, vaginal SCC, cervical carcinoma, and penile

138 in 32 of 48 cervical SCCs (67%) and 10 of 23 vulvar SCCs (43%).

139 sue from cases of cervical SCCs (n = 48) and vulvar SCCs (n = 23) were retrieved from the archives of

140 PD-L1 expression in a subset of cervical and vulvar SCCs and identifies a class of patients that are

141 ty occurring in synchronous skin surrounding vulvar SCCs, we investigated abnormalities in chromosome

142 iopsy specimens from 48 cervical SCCs and 23 vulvar SCCs.

143 ts, epithelial fibers were mainly present in vulvar segments and most nerve fibers were found in the

144 nal (SIR for men, 21.5; SIR for women, 7.8), vulvar (SIR, 14.8), vaginal (SIR, 5.9), cervical (SIR, 1

145 with SCC (1.8 +/- 0.4) compared with control vulvar skin (1.5 +/- 0.05).

146 an four FISH signals), whereas 56% of normal vulvar skin associated with cancer did.

147 al acute genital ulceration (NAGU) is a rare vulvar skin condition typically affecting girls and youn

148 Normal vulvar skin controls did not exhibit chromosome 17 polys

149 Lichen sclerosus is a chronic inflammatory vulvar skin disorder leading to severe itching, pain, sc

150 Controls of normal vulvar skin not associated with cancer were used for com

151 2 nonneoplastic, and 9 histologically normal vulvar skin samples.

152 e analyze lesional, nonlesional, and healthy vulvar skin using technologies including spatial and sin

153 aepithelial neoplasia (VIN), and surrounding vulvar skin were obtained from all vulvar excisions perf

154 The incidence of vulvar squamous cell carcinoma (2.3 cases per 100 000 pe

155 Vulvar squamous cell carcinoma (SCC) affects a spectrum

156 Vaginal and vulvar squamous cell carcinoma (SCC) are rare tumors tha

157 ular mechanism leading to the development of vulvar squamous cell carcinoma (VSCC) from vulvar lichen

158 Vulvar squamous cell carcinoma (VSCC), a rare gynecologi

159 The largest increase in vulvar squamous cell carcinoma between 2011 and 2021 was

160 improved CPR in women with locally advanced vulvar squamous cell carcinoma not amenable to surgical

161 Vulvar squamous cell carcinoma pathogenesis is tradition

162 cohort analysis of 36 patients with invasive vulvar squamous cell carcinoma where HPV status was dete

163 The incidence of cervical carcinoma, vulvar squamous cell carcinoma, and vaginal squamous cel

164 and 2021 (AAPC 8.0% [95% CI 5.3 to 13.9] for vulvar squamous cell carcinoma; 3.2% [0.5 to 6.6] for va

165 clerosis (VLS) may be complicated by loss of vulvar structure and vulvar carcinoma.

166 continue to reduce morbidity associated with vulvar surgery and groin node dissection.

167 a 15-month history of persistent, nonhealing vulvar ulcerations due to herpes simplex virus (HSV) typ

168 %; NPV range, 79%-80%; herpes simplex virus, vulvar ulcerations: sensitivity, 20%; specificity, 98%;

169 lthough the etiology of NAGU is unknown, the vulvar ulcers may result from an exuberant immune respon

170 nce of benefit was lacking for recurrence of vulvar, vaginal, and anal intraepithelial neoplasia, gen

171 omes included cervical, anal, oropharyngeal, vulvar, vaginal, and penile cancers, as well as genital

172 l types of human cancer, including cervical, vulvar, vaginal, penile, anal, and head-and-neck cancers

173 000 person-years for cervical carcinoma, and vulvar, vaginal, penile, oropharyngeal, and anal squamou

174 ulvar/vaginal cancer; RRs were increased for vulvar/vaginal cancer in families of anal cancer patient

175 In vulvar/vaginal cancer patients with SPC, 36.4% of deaths

176 1.68 (7.95-17.18), while that for concordant vulvar/vaginal cancer was 9.03 (7.31-11.15).

177 (1.34-7.74), and it was 2.72 (1.69-4.39) for vulvar/vaginal cancer; RRs were increased for vulvar/vag

178 Data on familial risks in penile and vulvar/vaginal cancers and in second primary cancers (SP

179 hrough 2015 to identify 3641 penile and 8856 vulvar/vaginal cancers and to calculate relative risks (

180 Vulvar/vaginal human papillomavirus (HPV) infections may

181 applying liquid lidocaine compresses to the vulvar vestibule before penetration.

182 RH, 3.54; 95% CI, 1.37-9.10), and history of vulvar warts (RH, 2.73; 95% CI, 1.27-5.87).